The Designing Safer Medicines in Discovery conference and exhibition (http://www.soci.org/General-Pages/Display-Event?EventCode=FCHEM310) brought together over 100 delegates from Pharma, Academia and CROs to discuss the emerging opportunities for reducing drug attrition. In the 1990s, issues with pharmacokinetics and drug metabolism were the major cause of drug failure in clinical development, but the industry has since put in place successful strategies to reduce the impact of ADME/DMPK. Now, drug toxicity has come to the fore, leading to an increased focus on drug safety and the development of early screening procedures to detect and mitigate its effects.
Read more about Safety First: Tackling the Major Cause of Drug Attrition »
